We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $519M
1-Year Est. Return 339.42%
This Fund
S&P 500
This Quarter Est. Return
+13.33%
1 Year Est. Return
+339.42%
3 Year Est. Return
+563.8%
5 Year Est. Return
+1,003.88%
10 Year Est. Return
–
AUM
$658M
AUM Growth
+$538M
Cap. Flow
+$551M
Cap. Flow %
83.75%
Top 10 Hldgs %
100%
Holding
8
New
4
Increased
–
Reduced
3
Closed
–

Top Buys

Rank Stock Value
1
ALXO icon
ALX Oncology
ALXO
+$381M
2
HRMY icon
Harmony Biosciences
HRMY
+$128M
3
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$47.1M
4
MTCR
Metacrine, Inc. Common Stock
MTCR
+$31.3M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$24.7M
2
DTIL icon
Precision BioSciences
DTIL
+$9.9M
3
VRNA
Verona Pharma
VRNA
+$1.78M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALXO icon
1
ALX Oncology
ALXO
$277M
$366M 55.63%
+9,699,925
New +$381M
HRMY icon
2
Harmony Biosciences
HRMY
$2.28B
$119M 18.06%
+3,504,624
New +$128M
AKRO
3
DELISTED
Akero Therapeutics
AKRO
$75.3M 11.44%
2,444,311
-705,708
-22% -$24.7M
CMPI
4
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$42.3M 6.43%
+3,673,374
New +$47.1M
MTCR
5
DELISTED
Metacrine, Inc. Common Stock
MTCR
$31.2M 4.75%
+3,059,123
New +$31.3M
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$15.1M 2.3%
501,584
– –
DTIL icon
7
Precision BioSciences
DTIL
$215M
$8M 1.22%
43,273
-49,780
-53% -$9.9M
VRNA
8
DELISTED
Verona Pharma
VRNA
$1.24M 0.19%
199,075
-257,695
-56% -$1.78M

Similar funds

CFA
Churchill Financial Advisors Louisville, Kentucky $519M AUM
CFG
Compton Financial Group Towson, Maryland $519M AUM 14.76% 1-Year Est. Return
MWM
Mindset Wealth Management Indianapolis, Indiana $519M AUM 46.03% 1-Year Est. Return
SWM
Scissortail Wealth Management Tulsa, Oklahoma $520M AUM 21.73% 1-Year Est. Return
WS
Wendel SE Paris $519M AUM 48.2% 1-Year Est. Return
GS
Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return
MWC
MBM Wealth Consultants Chesterfield, Missouri $519M AUM 16.88% 1-Year Est. Return
PDIP
Palo Duro Investment Partners Chicago, Illinois $518M AUM 22.62% 1-Year Est. Return

venBio Partners's Q3 2020 Portfolio in Review

As of Q3 2020, venBio Partners held 8 positions worth $658M, up 447% from $120M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners deployed $551M of net new capital in Q3 2020, opening 4 new positions. Its largest new stake was ALX Oncology: 9,699,925 shares worth $366M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Akero Therapeutics, an estimated $24.7M trimmed.

  • venBio Partners's largest Q3 2020 buy was ALX Oncology: 9,699,925 shares worth $366M.
  • venBio Partners's biggest Q3 2020 reduction was Akero Therapeutics, cutting an estimated $24.7M.
  • venBio Partners's ten largest holdings make up 100% of its $658M portfolio in Q3 2020.
  • venBio Partners opened 4 new positions and closed 0 in Q3 2020.
  • venBio Partners's portfolio value rose 447% quarter-over-quarter to $658M.

Based on venBio Partners's 13F filing for Q3 2020, filed 16 Nov 2020.